Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations

M. Gregová, J. Hojný, K. Němejcová, M. Bártů, M. Mára, B. Boudová, J. Laco, L. Krbal, I. Tichá, P. Dundr

. 2020 ; 26 (3) : 1527-1537. [pub] 20190831

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21020415

Grantová podpora
RVO 64165 Ministerstvo Zdravotnictví Ceské Republiky (CZ)
Progres Q28/LF1 Univerzita Karlova v Praze
UNCE 204065 Univerzita Karlova v Praze
SVV 260367 Univerzita Karlova v Praze
EF16_013/0001674 European Regional Development Fund
BBMRI_CZ LM2015089 European Regional Development Fund
CZ.2.16/3.1.00/24509 European Regional Development Fund

Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological, morphological, immunohistochemical and molecular findings focusing on FH in LBNs (n = 108) and compare it with the findings in usual leiomyomas (UL; n = 50) and leiomyosarcomas (LMS; n = 42). Immunohistochemically, loss of FH expression was found in 67/108 of LBN, 1/50 of UL and in no LMS. Class 4/5 FH mutations were detected in 15/53 LBN with sufficient DNA quality for molecular analysis. Pathogenic variants of the FH gene were detected in neither UL nor LMS. Local recurrence after surgery was present in 18/92 of LBN patients, 7 of which were histologically verified and 2 of which were found to be LBN. Our results confirmed that LBN behave in a benign fashion, although they may relapse. FH gene mutations were a common finding only in LBN, but not in UL and LMS. Immunohistochemistry with an antibody against FH seems to have a good sensitivity (87%) and moderate specificity (58%) with regard to predicting FH gene mutations and could be used as a screening method in tumors with features suggestive of FH alterations to identify patients who are at risk for the FH aberrations.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21020415
003      
CZ-PrNML
005      
20210830102118.0
007      
ta
008      
210728s2020 sz f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s12253-019-00739-5 $2 doi
035    __
$a (PubMed)31471882
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gregová, Mária $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
245    10
$a Leiomyoma with Bizarre Nuclei: a Study of 108 Cases Focusing on Clinicopathological Features, Morphology, and Fumarate Hydratase Alterations / $c M. Gregová, J. Hojný, K. Němejcová, M. Bártů, M. Mára, B. Boudová, J. Laco, L. Krbal, I. Tichá, P. Dundr
520    9_
$a Leiomyoma with bizarre nuclei (LBN) is an uncommon variant of uterine smooth muscle neoplasm. Involvement of fumarate hydratase (FH) has been suggested in the pathogenesis of a subset of LBN. The goal of our study is to assess the clinicopathological, morphological, immunohistochemical and molecular findings focusing on FH in LBNs (n = 108) and compare it with the findings in usual leiomyomas (UL; n = 50) and leiomyosarcomas (LMS; n = 42). Immunohistochemically, loss of FH expression was found in 67/108 of LBN, 1/50 of UL and in no LMS. Class 4/5 FH mutations were detected in 15/53 LBN with sufficient DNA quality for molecular analysis. Pathogenic variants of the FH gene were detected in neither UL nor LMS. Local recurrence after surgery was present in 18/92 of LBN patients, 7 of which were histologically verified and 2 of which were found to be LBN. Our results confirmed that LBN behave in a benign fashion, although they may relapse. FH gene mutations were a common finding only in LBN, but not in UL and LMS. Immunohistochemistry with an antibody against FH seems to have a good sensitivity (87%) and moderate specificity (58%) with regard to predicting FH gene mutations and could be used as a screening method in tumors with features suggestive of FH alterations to identify patients who are at risk for the FH aberrations.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a buněčné jádro $x patologie $7 D002467
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fumarasa $x genetika $7 D005649
650    _2
$a lidé $7 D006801
650    _2
$a leiomyom $x genetika $x patologie $7 D007889
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mutace $7 D009154
650    _2
$a nádory dělohy $x genetika $x patologie $7 D014594
655    _2
$a časopisecké články $7 D016428
700    1_
$a Hojný, Jan $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Němejcová, Kristýna $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Bártů, Michaela $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic
700    1_
$a Mára, Michal $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Boudová, Barbora $u Department of Obstetrics and Gynecology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic
700    1_
$a Laco, Jan $u The Fingerland Department of Pathology, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Charles University, Prague, Czech Republic
700    1_
$a Krbal, Lukáš $u The Fingerland Department of Pathology, Faculty of Medicine in Hradec Králové and University Hospital in Hradec Králové, Charles University, Prague, Czech Republic
700    1_
$a Tichá, Ivana $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. ivana.ticha@vfn.cz
700    1_
$a Dundr, Pavel $u Institute of Pathology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Studnickova 2, 12800, Prague 2, Czech Republic. pavel.dundr@vfn.cz
773    0_
$w MED00180530 $t Pathology oncology research : POR $x 1532-2807 $g Roč. 26, č. 3 (2020), s. 1527-1537
856    41
$u https://pubmed.ncbi.nlm.nih.gov/31471882 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830102119 $b ABA008
999    __
$a ok $b bmc $g 1691065 $s 1140861
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 26 $c 3 $d 1527-1537 $e 20190831 $i 1532-2807 $m Pathology oncology research $n Pathol Oncol Res $x MED00180530
GRA    __
$a RVO 64165 $p Ministerstvo Zdravotnictví Ceské Republiky (CZ)
GRA    __
$a Progres Q28/LF1 $p Univerzita Karlova v Praze
GRA    __
$a UNCE 204065 $p Univerzita Karlova v Praze
GRA    __
$a SVV 260367 $p Univerzita Karlova v Praze
GRA    __
$a EF16_013/0001674 $p European Regional Development Fund
GRA    __
$a BBMRI_CZ LM2015089 $p European Regional Development Fund
GRA    __
$a CZ.2.16/3.1.00/24509 $p European Regional Development Fund
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...